gastric cancer / Infection of Helicobacter pylori
Conditions
Interventions
None listed
Sponsors
The University of Tokyo Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) All persons who underwent at least one upper endoscopy or gastric X-ray between January 1, 2001 and December 31, 2023 at the screening medical institution. 2) Those who are 20 years of age or older at the time of the upper endoscopy or gastric X-ray (if the person undergoes the examination when he/she is under 20 years of age, he/she is not included, but if he/she undergoes the examination after 20 years of age, he/she is included in all cases). Participating Facilities 1) Japan Community Health Care Organization Shiga Hospital 2) Japanese Red Cross Society Kyoto Daini Hospital 3) Tsukuba Preventive Medicine Research Center 4) JA Kagoshima Koseiren Hospital 5) Yotsuya Medical Cube 6) Yamagata City Medical Association Medical Checkup Center 7) Medical Check-up Center Wellness 8) Tokushima Health Screening Centers 9) Nara Health Promotion Center 10) Uda City Hospital 11) Center for Digestive Endoscopy, Ibarakiken Medical Center 12) Kameda Makuhari Clinic 13) Kameda Medical Center 14) Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital 15) KKR Takamatsu Hospital 16) Center for Epidemiology and Preventive Medicine The University of Tokyo Hospital
Exclusion criteria
Exclusion criteria: Persons who did not receive permission to use data due to opt-out
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Association between the preventive effect of H. pylori eradication treatment and the development of gastric cancer | — |
Secondary
| Measure | Time frame |
|---|---|
| Specific evaluation items are planned to be as follows: a) Annual trends in the incidence of gastric cancer and gastric adenoma (including metachronous multiple cases) b) Annual trends in the incidence of esophageal cancer (including metachronous multiple cases) c) Annual trends in gastric cancer, gastric adenoma, and neoplastic diseases other than esophageal cancer (duodenal cancer, adenoma, etc.) d) Presence or absence of eradication treatment, degree of mucosal atrophy (Kimura-Takemoto classification), and time to onset of gastric cancer and gastric adenoma e) Presence or absence of eradication treatment, evaluation according to the Kyoto Gastritis Classification, and time to onset of gastric cancer and gastric adenoma f) Analysis of factors related to the prognosis of gastric cancer and gastric adenoma with or without eradication treatment g) Verification of the effect of Helicobacter pylori eradication treatment on the onset of gastric cancer and gastric adenoma h) Changes over time in the incidence rate of gastric cancer and gastric adenoma after eradication i) Annual trends in autoimmune gastritis and eosinophilic gastroenteritis j) Analysis of the relationship between autoimmune gastritis/eosinophilic gastroenteritis and the onset of gastric cancer/gastric adenoma k) Time to onset of esophageal cancer/duodenal epithelial tumors in groups with and without eradication therapy l) Analysis of factors related to the prognosis of esophageal cancer/duodenal epithelial tumors in groups with and without eradication therapy m) Verification of the effectiveness of eradication therapy in the onset of esophageal cancer/duodenal epithelial tumors | — |
Countries
Japan
Contacts
Public ContactYusuke Mitsui
The University of Tokyo Hospital Center for Epidemiology and Preventive Medicine
Outcome results
None listed